Want to see ACET full AI Analyst Report?
Top Page
Adicet Bio
(NASDAQ:ACET)
Select Model
Select Model
Rating:48Neutral
Price Target:
$4.00
▼(-55.56% Downside)
Action:Reiterated
Date:10/09/26
ACET’s score is held down primarily by weak financial performance (no meaningful revenue, sizable recurring losses, and heavy cash burn) and bearish technicals with the stock trading well below key moving averages. Offsetting these negatives, recent corporate updates provide meaningful pipeline catalysts (encouraging prula-cel autoimmune data, pivotal-trial preparation, and an IND-cleared program), but they do not fully mitigate near-term financing and execution risk.
Positive Factors
Prula-cel clinical evidence
Prula-cel has produced encouraging early efficacy in lupus nephritis, with many patients reaching renal response or remission while reducing immunosuppressant use. If these results are confirmed in pivotal testing, they could support a differentiated, one-time treatment model and materially expand Adicet’s development opportunity.
Negative Factors
No commercial revenue
The absence of marketed-product revenue means Adicet currently lacks an operating sales base to fund research, trials and corporate expenses. Its financial outlook therefore depends heavily on clinical success and future partnership or financing proceeds, making execution of the development pipeline central to long-term sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Prula-cel clinical evidence
Prula-cel has produced encouraging early efficacy in lupus nephritis, with many patients reaching renal response or remission while reducing immunosuppressant use. If these results are confirmed in pivotal testing, they could support a differentiated, one-time treatment model and materially expand Adicet’s development opportunity.
Read all positive factors
Adicet Bio (ACET) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$37.35M
Dividend Yield<0.01%
Average Volume (3M)300.56K
Price to Earnings (P/E)―
Beta (1Y)1.94
Revenue GrowthN/A
EPS Growth44.73%
CountryUS
Employees102
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-11.45
Shares Outstanding9,361,490
10 Day Avg. Volume205,939
30 Day Avg. Volume300,565
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap-0.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.31
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$25.00Price Target Upside177.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-6.36
Revenue Forecast (FY)N/A
Adicet Bio Business Overview & Revenue Model
Company Description
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen rece...
How the Company Makes Money
Adicet Bio does not have publicly established, recurring product revenue from marketed drugs (null for product sales), because it is a clinical-stage biotechnology company without approved commercial products. The company’s funding and revenue, wh...
Adicet Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 24.99M | 9.73M |
| Gross Profit | -1.34M | -6.38M | 0.00 | 0.00 | 24.99M | 9.73M |
| EBITDA | -93.16M | -110.39M | -110.65M | -136.53M | -67.04M | -60.41M |
| Net Income | -98.97M | -116.80M | -117.12M | -142.66M | -69.79M | -62.00M |
Balance Sheet | ||||||
| Total Assets | 148.17M | 192.35M | 220.22M | 207.29M | 330.69M | 338.94M |
| Cash, Cash Equivalents and Short-Term Investments | 118.19M | 158.53M | 176.30M | 159.71M | 257.66M | 277.54M |
| Total Debt | 12.85M | 14.74M | 17.23M | 20.92M | 21.02M | 20.94M |
| Total Liabilities | 28.03M | 33.15M | 33.61M | 37.12M | 38.35M | 35.81M |
| Stockholders Equity | 120.14M | 159.21M | 186.61M | 170.18M | 292.34M | 303.13M |
Cash Flow | ||||||
| Free Cash Flow | -84.97M | -96.98M | -93.50M | -98.18M | -61.55M | -64.10M |
| Operating Cash Flow | -84.53M | -95.25M | -92.38M | -93.72M | -44.77M | -51.05M |
| Investing Cash Flow | 7.83M | 2.39M | -119.24M | -4.46M | -16.78M | -2.80M |
| Financing Cash Flow | 75.08M | 75.25M | 111.31M | 236.00K | 41.51M | 242.69M |
Adicet Bio Technical Analysis
Negative
9.00
Price Trends
7.68
Negative
7.99
Negative
7.80
Negative
Market Momentum
-1.04
Positive
22.03
Positive
4.08
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACET, the sentiment is Negative. The current price of 9 is above the 20-day moving average (MA) of 5.54, above the 50-day MA of 7.68, and above the 200-day MA of 7.80, indicating a bearish trend. The MACD of -1.04 indicates Positive momentum. The RSI at 22.03 is Positive, neither overbought nor oversold. The STOCH value of 4.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACET.
Adicet Bio Risk Analysis
Adicet Bio disclosed 24 risk factors in its most recent earnings report. Adicet Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Adicet Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $37.35M | -0.35 | -74.90% | <0.01% | ― | 44.73% | |
48 Neutral | $95.90M | -0.89 | -78.11% | ― | ― | 9.38% | |
44 Neutral | $154.70M | -0.54 | 185.30% | ― | -56.25% | 30.97% | |
44 Neutral | $54.99M | -2.52 | -161.58% | ― | ― | 23.02% | |
41 Neutral | $300.67M | -1.86 | -53.86% | ― | ― | -7.24% |
* Healthcare Sector Average
ACET
Adicet Bio
3.99
-10.44
-72.35%
STRO
Sutro Biopharma
9.33
-2.27
-19.56%
PMVP
PMV Pharmaceuticals
1.27
-0.31
-19.62%
GANX
Gain Therapeutics
1.26
-0.69
-35.38%
IMMX
Immix Biopharma
8.15
4.76
140.41%
ARTV
Artiva Biotherapeutics, Inc.
6.15
1.11
22.02%
Adicet Bio Corporate Events
Business Operations and StrategyProduct-Related Announcements
Adicet Bio Advances Prula-cel Toward Pivotal Lupus Trial
Positive
Sep 28, 2026
On September 28, 2026, Adicet Bio reported Phase 1 data for its investigational therapy prula-cel in 22 patients with systemic lupus erythematosus, including 16 with lupus nephritis, with follow-up ranging from six to 21 months. At 12 months, 50% ...
Business Operations and StrategyProduct-Related Announcements
Adicet Bio Highlights Prula-cel Autoimmune CAR-T Pipeline Progress
Positive
Sep 8, 2026
On September 8, 2026, Adicet Bio posted an investor presentation outlining progress and key milestones across its pipeline of allogeneic gamma-delta1 CAR-T and in vivo CAR-T therapies, emphasizing prula-cel as a potential first off-the-shelf, one-...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Adicet Bio completes prula-cel Phase 1 SLE analysis
Positive
Sep 1, 2026
On September 1, 2026, Adicet Bio reported completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of prulacabtagene leucel (prula-cel) in systemic lupus erythematosus patients, with or without lupus nephritis, wit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.